Can a Bacterium or Virus Be the Root Cause of Your Cancer?

A Number That Quietly Rewrites the Story of Infection-Caused Cancer

One in eight. That is the fraction of all cancer diagnoses worldwide attributed to infection — not a rogue gene or a cigarette, but a bacterium or a virus. In September 2026, the International Agency for Research on Cancer and the World Health Organization put a hard number to it: 2.3 million new cancer cases in 2024 alone were caused by infection.

Let that sit for a moment. We have spent decades building a mental model of cancer as a story about DNA gone wrong — faulty inheritance, carcinogens inhaled or eaten, the slow accumulation of cellular mistakes. That model is true, and it is incomplete. A significant slice of the global cancer burden begins not with a mutation but with a pathogen, something you caught from another person.

The list of confirmed culprits has five main names: Helicobacter pylori, Human Papillomavirus, Hepatitis B, Hepatitis C, and the Epstein-Barr virus. The list is not closed. HIV and the Merkel cell polyomavirus were recently added as infection-related cancer drivers, a reminder that the catalogue of carcinogenic pathogens keeps growing as researchers look harder.

Here is the distinction that matters most for everything that follows. The infection is contagious. The resulting cancer is not. You can catch HPV from another person; you cannot catch cervical cancer. That gap between transmission and malignancy is exactly where prevention lives, and it is wider than most people realise. Understanding who the culprits are, and how they turn a common infection into a decades-long slow catastrophe, is where the story gets interesting.

Five Pathogens, Two Million Lives: Meet the Carcinogenic Usual Suspects

Start with the quiet ones. Helicobacter pylori, a spiral-shaped bacterium that thrives in the stomach's acidic murk, has colonised roughly half the human population. Most carriers feel nothing for decades.

Then, in some, the slow inflammation it kindles tips into stomach cancer — 760,000 new cases in 2024 attributed to this one microbe alone, making it the single most prolific carcinogenic pathogen on the planet.

Human Papillomavirus runs a close second at 750,000 cases. The numbers alone do not tell the full story: HPV is not one virus but a family of roughly 200 types, most harmless, a handful dangerous. The high-risk strains drive cervical cancer, yes, but also cancers of the throat, mouth, and anus — a range that surprises many people who think of HPV as a single, narrowly targeted threat.

It spreads without symptoms, which is precisely what makes it so effective at circulating undetected.

The hepatitis viruses, B and C, work differently — they target the liver specifically, and they do it over years. Hepatitis B was responsible for 360,000 infection-linked cancer cases in 2024; Hepatitis C added 160,000 more. Together they account for the majority of the world's liver cancer burden, a disease that remains stubbornly hard to treat once established.

Then there is the one that surprises nearly everyone. Epstein-Barr virus causes mononucleosis, the exhausting "kissing disease" that lays teenagers flat for weeks. Most adults carry it permanently, dormant, forgotten. Yet EBV is linked to 260,000 cancer cases annually, including lymphomas and a subset of stomach cancers.

It reactivates under the right conditions, and when it does, the consequences can be severe. No widely available vaccine exists for it — a gap that sits conspicuously at the edge of what medicine can currently offer.

The Long Slow Burn: How a Germ Becomes a Tumour

Most infections announce themselves. Scabies itches furiously; pertussis produces that unmistakable whooping cough. The body raises an alarm, and you act. The infections that cause cancer are quieter — so quiet that decades can pass before the damage surfaces.

Here is the mechanism. When H. pylori colonises the stomach lining, it triggers a low-grade inflammation that never fully resolves. The immune system keeps fighting; the tissue keeps repairing itself; and every cycle of damage-and-repair is a cycle in which a cell can copy its DNA imperfectly. Do that enough times over enough years, and the arithmetic of error tips toward malignancy.

The germ is long gone from the story by the time the tumour appears — or still quietly present, unremarkable, unsuspected.

This is why these pathogens are so practically treacherous. A rising scabies count in Estonia at least signals something is wrong; dermatologists are seeing more cases, and parents know to look. H. pylori and Hepatitis C offer no such signal — a carrier spreads them without a cough, a rash, or a single symptomatic day.

The practical implication cuts both ways. Because the pathway from infection to cancer runs over decades, there is a long window to intervene. H. pylori can be cleared with a standard course of antibiotics; Hepatitis C, once nearly untreatable, now yields to a short course of antivirals with cure rates above 95 percent.

Treat the infection, and you interrupt the slow burn before it reaches its destination. The cancer never starts.

That is not a small thing. That is the whole point.

Estonia's Quietly Ambitious Experiment in Early Detection

Picture a lab technician in Tartu, sometime in 2021, retiring a piece of equipment. The Pap smear — decades of faithful, if imperfect, service — was replaced not by something flashier, but by something more honest: HPV DNA screening. Where the Pap test waited for cells to look wrong, the new test asked a different question entirely: is the virus here?

That shift, from reactive to proactive logic, sounds administrative. It is actually a change in philosophy.

The backdrop matters. Estonia recorded 9,835 new primary cancer cases in 2023. A meaningful slice of that number traces back to pathogens, which means it is, in principle, a tractable target. Not all cancers are — the pathogen-driven ones carry the rare quality of being upstream of the damage, reachable before the tumour exists.

Then came 2024, and a small cardboard box in the post. Home HPV testing kits, sent to women who had not shown up for clinic-based screening. The logic is simple and, frankly, overdue: if the barrier is the waiting room, remove the waiting room. A swab, an envelope, a result.

Whether you live in Tallinn or a village two buses from anywhere, the offer is the same.

Whether it is working, in the deep statistical sense, is still an open question. TalTech and health data researchers are watching the numbers, tracking whether expanded access in 2024 translates to fewer cervical cancer diagnoses in 2034 or 2044. That is the uncomfortable timescale of prevention: you plant it now and your successor counts the harvest.

The experiment is running. The results are not yet in.

The 90% Solution: What a Vaccine Can Actually Prevent

Compare two futures. In the first, a twelve-year-old receives two doses of HPV vaccine before any sexual contact, and roughly nine in ten HPV-related cancers that might otherwise have grown in her throat, cervix, or mouth simply never start. In the second, the vaccination window passes, the virus establishes itself silently over a decade, and treatment arrives when the cancer already has.

The difference between those two futures is not technology. The technology exists. The difference is timing.

Estonia has chosen the first future, at least on paper. Tervisekassa covers HPV vaccination free of charge for both girls and boys aged twelve to fourteen, precisely because that window — before sexual debut — is when the vaccine's protection is near-total. Ninety percent prevention is a number medicine rarely gets to use.

Chemotherapy and surgery fight the disease that arrived; vaccination prevents the infection that would have caused it. Primary prevention — stopping the pathogen before it ever settles in — is categorically a different kind of medicine, and a cheaper one.

The contrast with Epstein-Barr virus makes that gap visible. EBV is linked to 260,000 cancer cases a year, including lymphomas and some stomach cancers, and there is no vaccine for it. Nothing equivalent stands upstream of those cases.

HPV had its vaccine by 2006; EBV research is still circling the problem decades later. One infection gets a near-total upstream shield. The other gets surveillance and hope. That asymmetry, for now, is simply where the science stands.

When Trust Becomes a Risk Factor: Hesitancy, Scabies, and the Open Horizon

In the chemotherapy ward at North Estonia Medical Centre, an oncologist named Kadri Putnik has been asked a question that would have seemed absurd a decade ago: "Did my cancer come from the COVID-19 vaccine?" The patient asking it is not foolish. They are frightened, and they are swimming in a current of eroding trust in evidence-based medicine.

But the fear itself is the risk factor here, because the same hesitancy that delays a vaccine against HPV or a screening for H. pylori is the hesitancy that lets a carcinogen run a decade unchallenged.

Meanwhile, school health nurse Kristel Veidenbaum is watching scabies spread through Estonian classrooms, higher rates clustering among children and young adults. "Statistics are no longer kept," she notes, because the mite surrenders to over-the-counter cream and leaves no official trace. That invisibility is not reassuring — pathogens that evade counting tend to find gaps in immunity and screening that harder-to-see carcinogens also use.

Then there is the experiment still running. Home HPV test kits arrived in Estonia in 2024. Whether they will bend the cancer mortality curve in 2034 is genuinely unmeasured. For EBV, which quietly seeds 260,000 cases a year, no vaccine even exists yet. We still don't know. That, honestly, is the best part — because it means the next chapter of this long human struggle against infection-caused cancer is still being written.